Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction

A Randomized, Evaluator-blinded, Parallel Group, Comparator-controlled, Multicenter Study to Evaluate the Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies

A prospective, randomized, evaluator-blinded, comparator-controlled, parallel group, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies

Study Overview

• Status: Withdrawn
• Conditions: Cheek Wrinkles; Midface Contour Deficiencies
• Intervention / Treatment: Device: GP0112; Device: Restylane Lyft Lidocaine

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Cologne, Germany, 50996
    • Galderma Research Site
  • Darmstadt, Germany, 64283
    • Galderma Research Site
  • Duesseldorf, Germany, 40212
    • Galderma Research Site
  • Duesseldorf, Germany, 40545
    • Galderma Research Site
  • Hamburg, Germany, 20146
    • Galderma Research Site
  • Hamburg, Germany, 22609
    • Galderma Research Site
  • Munich, Germany, 80469
    • Galderma Research Site
  • Wuppertal, Germany, 42287
    • Galderma Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Ability to adequately understand the verbal explanations and the written subject information provided in local language and ability and willingness to give consent to participate in the study. Signed and dated informed consent to participate in the study.
2. Men and non-pregnant, non-breastfeeding women aged 18 years or older.
3. MMVS grade of 2, 3 or 4 (mild to substantial loss of fullness in the midface area) on each side of the face as assessed by the Blinded Evaluator. The MMVS for each side of the face does not need to be equal, however the difference between the two sides should be limited to 1 grade.
4. Subjects willing to abstain from any other facial plastic surgical or cosmetic procedures below the level of the lower orbital rim for the duration of the study (e.g., laser or chemical resurfacing, needling, facelift, lifting threads, radiofrequency etc.).

5. Intent to undergo treatment for correction of midface volume deficit.

   Inclusion criteria 6-7 apply to female subjects only

6. If the subject is a female of childbearing potential, she agrees to use an acceptable form of effective birth control for the duration of the study and is willing to take a urine pregnancy test (UPT) at the screening/baseline visit, prior to treatment/injection, and at the end of study visit.
7. Negative UPT for women of childbearing potential at the screening/baseline visit and all injection visits.

Exclusion Criteria:

1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins.
2. Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics or nerve blocking agents (if intended to be used for that subject).
3. Previous or present severe or multiple allergies manifested by severe reactions, such as anaphylaxis or angioedema, or family history of these conditions.
4. Previous facial surgery (e.g. facial fat removal, facelift and sinus surgery) in or near the treatment area that in the Treating Investigator´s opinion could interfere with the study safety and/or effectiveness assessments.

5. Any previous aesthetic procedures or implants:

   • Previous use of any permanent (non-biodegradable) or semi-permanent (e.g., calcium hydroxylapatite or Poly-L-Lactic acid) facial tissue augmentation therapy, lifting threads, permanent implants or autologous fat in the face regardless of time.
   • Previous HA filler or collagen filler in or near the treatment area within 12 months.
   • Previous botulinum toxin treatment in or near the treatment area within 6 months.
   • Previous energy based aesthetic procedures (e.g. laser, intense pulsed light, radiofrequency and ultrasound) in or near the treatment area within 6 months.
   • Previous mechanical (e.g. dermabrasion, needling) or chemical aesthetic procedures (e.g. chemical peel) in or near the treatment area within 6 months.
   • Previous treatment with cryotherapy in or near the treatment area within 6 months.
6. History of cancer or previous radiation near or on the area to be treated.

7. Presence of any disease or lesions near or on the area to be treated, e.g.,

   • Inflammation, active or chronic infection (e.g., in mouth, dentals, head);
   • Facial psoriasis, eczema, acne, rosacea, perioral dermatitis, herpes simplex or herpes zoster;
   • Scars or deformities;
   • Cancer, or precancerous conditions (e.g. actinic keratosis or actinic cheilitis).
8. Evidence of scar-related disease or delayed healing activity within 1 year prior to the baseline visit, or subjects susceptible to keloid formation, hyperpigmentation or hypertrophic scarring.
9. Presence of tattoo, piercing, beard or facial hair, which, in the Treating Investigator's opinion, would interfere with the study injections and/or study assessment.
10. Presence of a dental, oral, or facial condition which, in the Treating Investigator's opinion, would interfere with the study injections and/or study assessment; e.g. has dentures or any device covering all or part of the upper palate, and/or severe malocclusion or dentofacial or maxillofacial deformities. Any planned procedure (e.g. dental implants, tooth extractions, orthodontia) during the study period, that would make the subject unsuitable for inclusion in the opinion of the Investigator.
11. An underlying known disease, a surgical or medical condition that would expose the subject to undue risk, e.g. human immunodeficiency virus (HIV), active hepatitis, autoimmune disease, history of bleeding disorders, connective tissue diseases such as rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis, or scleroderma.
12. Use of concomitant medication that have the potential to prolong bleeding times such as anticoagulants or inhibitors of platelet aggregation (e.g. aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), Omega 3 or Vitamin E), within 14 days prior to injection. Omega 3 and Vitamin E are acceptable only as part of a standard multivitamin formulation.
13. Treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. immunosuppressive monoclonal antibodies, antiviral treatment for HIV or hepatitis).
14. Treatment with systemic corticosteroids (inhaled corticosteroids are allowed) within 3 months prior to Baseline visit.
15. Use of topical facial corticosteroids or prescription retinoids near or on the area to be treated within 1 month of the Baseline visit or systemic retinoid treatment within 6 months of the Baseline visit, or plan to receive such treatment during participation in the study.

16. Presence of any condition or situation, which in the opinion of the Treating Investigator makes the subject unable to complete the study per protocol, e.g.

    • Subject is not likely to avoid other prohibited facial cosmetic treatments;
    • Subject is not likely to complete the study because of other commitments;
    • Subject is anticipated to be unavailable for visits, incapable of understanding the investigational assessments or having unrealistic expectations of treatment result;
    • Subject who has a concomitant condition (e.g. acute viral or bacterial infection with fever) that might confuse or confound study treatments or assessments.
17. Subject who plan to lose or has a medical condition that may cause them to lose a significant amount of weight during the course of the study.
18. Study center personnel, close relatives of the study center personnel (e.g. parents, children, siblings, or spouse), employees or close relatives of employees at the Sponsor company.
19. Participation in any other interventional clinical study within 30 days before treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GP0112; Single injection and optional touch up injection with GP0112	Device: GP0112; Injectable gel
Active Comparator: Restylane Lyft Lidocaine; Single injection and optional touch up injection with Restylane Lyft Lidocaine	Device: Restylane Lyft Lidocaine; Injectable gel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Demonstrate non-inferiority of GP0112 versus a comparator-control in cheek augmentation and correction of midface contour deficiencies	Change from baseline based on the Blinded Evaluator's live assessment of midface fullness using the 4-grade photograph-based Medicis Midface Volume Scale (MMVS)	3 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effectiveness of GP0112 and comparator-control based on the Medicis Midface Volume Scale (MMVS) assessment	Responder rate based on the Blinded Evaluator's live assessment of the Medicis Midface Volume Scale (MMVS)	6, 9, 12 and 13 Months
Effectiveness of GP0112 on the Global Aesthetic Improvement Scale (GAIS)	Percentage of responders, defined by having at least "Improved" (improved, much improved or very much improved) on the Global Aesthetic Improvement Scale (GAIS) as assessed by the subject and treating investigator	3, 6, 9, 12 and 13 Months
Effectiveness of GP0112 and comparator-control using the FACE-Q	Change from baseline in subject satisfaction using FACE-Q Satisfaction with Cheeks and Satisfaction with Outcome questionnaires	3, 6, 9, 12 and 13 Months
Effectiveness of GP0112 and comparator-control using Subject Satisfaction Questionnaire	Proportion of subjects in each response category for every question in the Subject Satisfaction Questionnaire	3, 6, 9, 12 and 13 Months
Effectiveness of GP0112 and comparator-control in returning to social engagement	Time in hours until the subject feels comfortable returning to social engagement after treatment, based on subject diary reporting	3, 6, 9, 12 and 13 Months
Safety of GP0112 in cheek augmentation and correction of midface contour deficiencies adverse events (AEs)	Incidence, intensity, time to onset and duration of adverse events	Up to 13 Months
Safety of GP0112 in cheek augmentation and correction of midface contour pre-defined expected post-treatment events	Incidence, intensity and number of days of pre-defined expected post-treatment events collected using subject diaries for 14 days following each treatment	Up to 13 Months

Collaborators and Investigators

• Sponsor: Galderma R&D

Study record dates

Study Major Dates

• Study Start (Anticipated): February 22, 2022
• Primary Completion (Anticipated): February 19, 2023
• Study Completion (Anticipated): November 18, 2023

Study Registration Dates

• First Submitted: September 16, 2021
• First Submitted That Met QC Criteria: October 18, 2021
• First Posted (Actual): October 28, 2021

Study Record Updates

• Last Update Posted (Actual): August 25, 2022
• Last Update Submitted That Met QC Criteria: August 24, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Membrane Transport Modulators; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Lidocaine
• Other Study ID Numbers: 43N1EU2008

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No